The coverage criteria specify that TMS treatment must be administered by an FDA-cleared device in accordance with FDA labeled indications. Aetna is one of the largest health plans in the country with over 19.4 million lives covered through its commercial policies nationwide. The TMS policy update is effective immediately. For more information about NeuroStar TMS Therapy, please visit www.neurostar.com. About Neuronetics MALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medic ...

Medi-Cal is California's Medicaid healthcare program. It offers no-cost and low-cost health coverage for children and adults with limited income and resources who meet eligibility requirements. Medi-Cal policies impact 14.8 million covered lives in California. The TMS policy update will go into effect on August 1, 2024. "At a time when mental health services are more essential than ever, expanded access to NeuroStar TMS through Medi-Cal is a pivotal step in addressing the growing need for care among both ad ...

Medi-Cal is California's Medicaid healthcare program. It offers no-cost and low-cost health coverage for children and adults with limited income and resources who meet eligibility requirements. Medi-Cal policies impact 14.8 million covered lives in California. The TMS policy update will go into effect on August 1, 2024. Neuronetics is the first and only TMS company with FDA clearance for the treatment of adolescents and the only company in the industry with a dedicated health policy team that partners with ...

BCBS Michigan covers 4.9 million lives in the state of Michigan, and the policy includes TMS access for members 15-70 years of age. Cambia Health Solutions is the parent company of Regence BCBS, Asuris Health, and BridgeSpan Health, which covers 2.5 million lives throughout the states of Washington, Utah, Oregon, and Idaho. The policy allows TMS eligibility for ages consistent with device-specific FDA indication. The effective date for both policies is September 1, 2024. For more information about NeuroStar ...

BCBS Michigan covers 4.9 million lives in the state of Michigan, and the policy includes TMS access for members 15-70 years of age. Cambia Health Solutions is the parent company of Regence BCBS, Asuris Health, and BridgeSpan Health, which covers 2.5 million lives throughout the states of Washington, Utah, Oregon, and Idaho. The policy allows TMS eligibility for ages consistent with device-specific FDA indication. The effective date for both policies is September 1, 2024. BCBS of Michigan and Cambia's Regenc ...

Better Me Provider Program is an extensive commercial initiative to support practices committed to meeting patient care and responsiveness standards. These standards are developed in collaboration with TMS medical experts, ensuring prompt response times by a dedicated NeuroStar coordinator, who advises patients about the benefits of the entire course of NeuroStar treatment, along with optimizing websites and social media content to educate patients. It is designed to help people with major depressive disord ...

"The Better Me Provider Program is an approach that considers the entire patient journey, providing an optimal experience to get the help they need faster," stated Keith J. Sullivan, President and CEO of Neuronetics, Inc. "We are excited for more NeuroStar providers to participate in the program and continue to make our lifechanging treatment more accessible to the 29 million people suffering from MDD, OCD, and anxious depression." Improved response times: Participating practices raised the bar for response ...

MALVERN, Pa., July 01, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the national launch of the Better Me Provider (BMP) program, pioneering new standards in patient care and responsiveness to improve treatment accessibility within the mental health industry. The providers participating in the program are committed t ...

The following data will be presented: The Impact of Treatment Gaps on Effectiveness of Transcranial Magnetic Stimulation in MDD Presented by: Sonder Behavioral Health & Wellness, Minnetonka, Minnesota Overview: This study will showcase feasibility, safety, and efficacy results using NeuroStar with a pragmatic accelerated TMS protocol without the need for neuroimaging. Presentation Date: June 14th at 4:00 PM BST Presenter: Dr. Kenneth Pages, Medical Director of TMS of South Tampa Overview: Dr. Pages will con ...

"We are thrilled to present this meaningful evidence at the Clinical TMS Society Annual Meeting and engage with TMS providers and researchers about recent advancements in our field," said Cory Anderson, Senior Vice President of Research & Development and Clinical Affairs. "Our extensive data and strong clinical presence establish NeuroStar as the leading TMS device, treating the highest number of patients and supporting providers in delivering exceptional patient care in clinical settings." When to Hold and ...